Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
6
Neutral
3
Bullish
5
Bearish
6
Neutral
3
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Bearish
6
Neutral
3
Bullish
5
Bearish
6
Neutral
3
Bullish
5
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Mankind Pharma Limited is a leading Indian pharmaceutical company engaged in manufacturing and marketing a broad spectrum of pharmaceutical products and healthcare solutions. The company operates in both acute and chronic therapeutic areas, with a notable presence in cardiovascular, anti-diabetic, and neuro/CNS segments.
In Q3 FY26, Mankind Pharma reported a revenue increase of 11.5% YoY, driven by strong domestic pharmaceutical performance. Adjusted EBITDA margins improved to 25.9%, showcasing robust operational efficiency.
The expansion into specialty and super specialty segments via BSV acquisition has marked significant growth, with BSV now contributing substantially to Mankind's revenue and offering a high entry barrier to competitors.
Mankind Pharma's consumer healthcare segment showed resilience with a 5.2% growth in Q3 FY26, bolstered by high-performing brands like Gas-O-Fast and Manforce, and increasing contributions from e-commerce and modern trade channels.
Strategic transformations in workforce and operational strategies have bolstered Mankind's foundation, positioning it for sustainable long-term growth and enhanced market position across its pharma and consumer healthcare segments.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,04,376 Cr
Low Risk
48.9
37.0
3.9
6.4
2,640.30
1,909.90
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1145.25 | 1,14,239 Cr | 25.43 | 4.21 | 0.09 | 18.59 | 17.35 | 8.57 | ||
1346.85 | 1,08,808 Cr | 32.34 | 3.16 | 0.97 | 11.27 | 14.95 | 7.92 | ||
1989.00 | 1,07,468 Cr | 98.53 | 20.28 | 0.10 | 16.77 | 16.14 | 10.38 | ||
2527.00 | 1,04,376 Cr | 50.48 | 6.40 | 0.04 | 11.74 | 13.13 | 7.36 | ||
1200.10 | 1,00,170 Cr | 31.47 | 2.63 | 0.67 | 11.07 | 12.54 | 5.48 | ||
1675.00 | 96,376 Cr | 25.97 | 2.54 | 0.24 | 9.25 | 11.76 | 6.34 | ||
2029.00 | 92,784 Cr | 16.71 | 4.13 | 0.89 | 23.76 | 24.88 | 14.47 | ||
| Median: 7 Co. | — | 1675.00 | 1,04,376 Cr | 31.47 | 4.13 | 0.24 | 11.74 | 14.95 | 7.92 |
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Mankind Pharma Ltd (MANKIND) is currently trading at 2,527.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Mankind Pharma Limited is a leading Indian pharmaceutical company engaged in manufacturing and marketing a broad spectrum of pharmaceutical products and healthcare solutions. The company operates in both acute and chronic therapeutic areas, with a notable presence in cardiovascular, anti-diabetic, and neuro/CNS segments. In Q3 FY26, Mankind Pharma reported a revenue increase of 11.5% YoY, driven by strong domestic pharmaceutical performance. Adjusted EBITDA margins improved to 25.9%, showcasing robust operational efficiency. The expansion into specialty and super specialty segments via BSV acquisition has marked significant growth, with BSV now contributing substantially to Mankind's revenue and offering a high entry barrier to competitors. Mankind Pharma's consumer healthcare segment showed resilience with a 5.2% growth in Q3 FY26, bolstered by high-performing brands like Gas-O-Fast and Manforce, and increasing contributions from e-commerce and modern trade channels. Strategic transformations in workforce and operational strategies have bolstered Mankind's foundation, positioning it for sustainable long-term growth and enhanced market position across its pharma and consumer healthcare segments.
Over the past 52 weeks, Mankind Pharma Ltd has traded between a low of ₹1,909.90 and a high of ₹2,640.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Mankind Pharma Ltd has a market capitalization of approximately 1,04,376.49. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Mankind Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 48.93 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,04,376.49 Cr, Mankind Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Mankind Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Mankind Pharma Ltd is 48.93. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
He ceased to be an Independent Director with effect from August 30, 2026, after completing his second term, as disclosed by the company.
Jefferies has reiterated a Buy rating and raised its target price to Rs 3,000 from Rs 2,870, implying 19% upside in its note.
Revenue from operations rose 11.8% YoY to INR 3,443 crore, while PAT increased 30.4% YoY to INR 559 crore in Q4 FY26.
Mankind Pharma reported revenue from operations of INR 3,697 crore in Q2FY26, a 20.8% increase year-on-year.
